{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T21:51:28Z","timestamp":1768686688727,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.lpm.2024.104223","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T01:04:02Z","timestamp":1706835842000},"page":"104223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Towards etiological treatments in cardiomyopathies"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8141-6582","authenticated-orcid":false,"given":"Olivier","family":"Lairez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romain","family":"Itier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9reng\u00e8re","family":"Bachelet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Huart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2024.104223_bib0001","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1093\/eurheartj\/ehn309","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Hear","volume":"29","author":"Dickstein","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2024.104223_bib0002","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2024.104223_bib0003","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2024.104223_bib0004","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJM199908193410806","article-title":"Hormones and hemodynamics in heart failure","volume":"341","author":"Schrier","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104223_bib0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2017.02.008","article-title":"The design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) trial","volume":"187","author":"Ho","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.lpm.2024.104223_bib0006","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2024.104223_bib0007","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1172\/JCI116676","article-title":"Bioenergetic abnormalities associated with severe left ventricular hypertrophy","volume":"92","author":"Zhang","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.lpm.2024.104223_bib0008","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1161\/CIRCULATIONAHA.109.934059","article-title":"Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy","volume":"122","author":"Abozguia","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2024.104223_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2021.06.010","article-title":"Randomized controlled trial of pErhexiline on regreSsion of left Ventricular hypErtrophy in patients with symptomatic hypertrophic CardioMyopathy (RESOLVE-HCM Trial)","author":"Ananthakrishna","year":"2021","journal-title":"Am Heart J"},{"key":"10.1016\/j.lpm.2024.104223_bib0010","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/cvr\/cvv247","article-title":"Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy","volume":"109","author":"Flenner","year":"2016","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.lpm.2024.104223_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","article-title":"Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study","volume":"11","author":"Olivotto","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.lpm.2024.104223_bib0012","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1177\/1535370218813988","article-title":"Trientine selectively delivers copper to the heart and suppresses pressure overload-induced cardiac hypertrophy in rats","volume":"243","author":"Liu","year":"2018","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.lpm.2024.104223_bib0013","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2024.104223_bib0014","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.122.014986","article-title":"Myosin inhibition and left ventricular diastolic function in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: insights from the VALOR-HCM study","volume":"15","author":"Cremer","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.lpm.2024.104223_bib0015","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of Mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2024.104223_bib0016","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of Aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2024.104223_bib0017","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.acvd.2019.01.002","article-title":"Fabry disease in cardiology practice: literature review and expert point of view","volume":"112","author":"Hag\u00e8ge","year":"2019","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.lpm.2024.104223_bib0018","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104223_bib0019","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J Med Genet"},{"key":"10.1016\/j.lpm.2024.104223_bib0020","article-title":"Understanding and modifying Fabry disease: rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study","volume":"31","author":"Wanner","year":"2022","journal-title":"Mol Genet Metab reports"},{"key":"10.1016\/j.lpm.2024.104223_bib0021","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jimd.12080","article-title":"Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year Phase 1\/2 clinical trial","volume":"42","author":"Schiffmann","year":"2019","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.lpm.2024.104223_bib0022","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","article-title":"AL Amyloidosis: current chemotherapy and immune therapy treatment strategies: JACC: cardiooncology state-of-the-art review","volume":"3","author":"Bianchi","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.lpm.2024.104223_bib0023","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104223_bib0024","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104223_bib0025","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.lpm.2024.104223_bib0026","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","article-title":"Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy","volume":"74","author":"Judge","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2024.104223_bib0027","series-title":"ATTRibute-CM trial. hot line sess","author":"Gillmore","year":"2023"},{"key":"10.1016\/j.lpm.2024.104223_bib0028","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2024.104223_bib0029","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with Patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.lpm.2024.104223_bib0030","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104223_bib0031","series-title":"Patisiran treatment for ATTR cardiac amyloidosis: 18-month results of the phase 3 APOLLO-B study","author":"Fontana","year":"2023"},{"key":"10.1016\/j.lpm.2024.104223_bib0032","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104223_bib0033","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature09494","article-title":"Antibodies to human serum amyloid P component eliminate visceral amyloid deposits","volume":"468","author":"Bodin","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.lpm.2024.104223_bib0034","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104223_bib0035","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.lpm.2024.104223_bib0036","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2022019406","article-title":"Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial","volume":"142","author":"Gertz","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.lpm.2024.104223_bib0037","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1038\/s41467-021-23274-x","article-title":"A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells","volume":"12","author":"Michalon","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.lpm.2024.104223_bib0038","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104223_bib0039","first-page":"86","article-title":"Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin","volume":"23","author":"Higaki","year":"2016","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis"},{"key":"10.1016\/j.lpm.2024.104223_bib0040","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/eurheartj\/ehz695","article-title":"A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functional recovery in an experimental model","volume":"41","author":"George","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2024.104223_bib0041","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/CIRCULATIONAHA.110.981738","article-title":"Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease","volume":"123","author":"Stasch","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2024.104223_bib0042","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104223_bib0043","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/ehf2.12628","article-title":"The aptamer BC 007 for treatment of dilated cardiomyopathy: evaluation in Doberman Pinschers of efficacy and outcomes","volume":"7","author":"Werner","year":"2020","journal-title":"ESC Hear Fail"},{"key":"10.1016\/j.lpm.2024.104223_bib0044","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with Omecamtiv Mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2024.104223_bib0045","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/jama.2022.11016","article-title":"Effect of Omecamtiv Mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction: the METEORIC-HF randomized clinical trial","volume":"328","author":"Lewis","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.lpm.2024.104223_bib0046","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/ejhf.1933","article-title":"Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial","volume":"22","author":"Voors","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.lpm.2024.104223_bib0047","doi-asserted-by":"crossref","first-page":"H585","DOI":"10.1152\/ajpheart.00369.2023","article-title":"Predominant myosin superrelaxed state in canine myocardium with naturally occurring dilated cardiomyopathy","volume":"325","author":"Ochala","year":"2023","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.lpm.2024.104223_bib0048","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1161\/CIRCRESAHA.123.323304","article-title":"DWORF extends life span in a PLN-R14del cardiomyopathy mouse model by reducing abnormal sarcoplasmic reticulum clusters","volume":"133","author":"Stege","year":"2023","journal-title":"Circ Res"},{"key":"10.1016\/j.lpm.2024.104223_bib0049","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.38319","article-title":"The DWORF micropeptide enhances contractility and prevents heart failure in a mouse model of dilated cardiomyopathy","volume":"7","author":"Makarewich","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.lpm.2024.104223_bib0050","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ymthe.2019.12.011","article-title":"Single SERCA2a therapy ameliorated dilated cardiomyopathy for 18 months in a mouse model of Duchenne muscular dystrophy","volume":"28","author":"Wasala","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.lpm.2024.104223_bib0051","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027480","article-title":"Dwarf Open Reading Frame (DWORF) gene therapy ameliorated Duchenne muscular dystrophy cardiomyopathy in aged mdx mice","volume":"12","author":"Morales","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.lpm.2024.104223_bib0052","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1002\/ehf2.13360","article-title":"Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy","volume":"8","author":"Devesa","year":"2021","journal-title":"ESC Hear Fail"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498224000010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498224000010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:10:32Z","timestamp":1760105432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498224000010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0755498224000010"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2024.104223","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards etiological treatments in cardiomyopathies","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2024.104223","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104223"}}